A cost-effectiveness approach to drug subsidy and pricing in Australia

Health Affairs

Volumn 20, Issue 3, 2001, Pages 104-114

  Birkett, Donald J ^a   Mitchell, Andrew S ^b   McManus, Peter ^c  

^a FLINDERS UNIVERSITY   (Australia)

^b DEPARTMENT OF HEALTH   (Australia)

^c Drug Utilization Sub Committee   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; COST; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; FEE; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HUMAN; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PUBLIC HEALTH; PUBLICATION;

AUSTRALIA; COST SHARING; COST-BENEFIT ANALYSIS; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; FINANCING, GOVERNMENT; FORMULARIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; NATIONAL HEALTH PROGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); RATE SETTING AND REVIEW;

EID: 0035351404     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.20.3.104     Document Type: Article

References (9)

1. See M Angell, "The Pharmaceutical Industry - To Whom Is It Accountable?" New England Journal of Medicine 342, no. 25 (2000): 1902-1904.
2. Universal Currency Converter, 〈www.xe.net/ucc〉.
3. The full guidelines are available from the Commonwealth Department of Health and Aged Care, 〈www.health.gov.au:80/haf/docs/pharmpac/gusubpac.htm〉 (November 2000).
4. "Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners" (Canberra: Australian Government Publishing Service, 1 August 2000).
5. S.R. Hill et al., "Problems with the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme," Journal of the Amcrican Mcdical Association 283, no. 16 (2000): 2116-2121.
6. Full results are in B. George, A. Harris, and A. Mitchell, "Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia, 1991-1996" (Submitted to Pharmacoeconomics).
7. Unpublished data from the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee, Department of Health and Aged Care, Canberra, Australia.
8. S. Jacobzone, "Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals," Labour Market and Social Policy Occasional Papers no. 40 (Paris: Organization for Economic Cooperation and Development, April 2000).
9. Health Insurance Commission, Canberra, Australia, 〈www.hic.gov.au/statistics/index.htm〉 (March 2001).